Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging Bioidentical Hormones - U.S. Senate Special Committee on Aging
Post-WHI: Additional Issues Are hormone effects different if started immediately after menopause? - Secondary analyses of combined WHI Trials * Women starting hormones close to the menopause may have fewer heart attacks and deaths compared to the increases in women distant from the menopause * Stroke and breast cancer increased irrespective of years since menopause * Provides some reassurance that younger women using hormones for the short term for relief of hot flashes and night sweats are not at increased risk of heart disease * Older women with hot flashes and night sweats are at high risk if they start hormone therapy - Ongoing surrogate outcome trials (imaging studies of coronary and brain arteries) in younger women - Findings should not be taken to imply that any early benefit for coronary disease will persist into older ages * Would estradiol have had a different effect? * Role of route of administration (ltransdermal versus oral)
Statement of the American Pharmacists Association 230 On
- Page 181 and 182: EFFECTS OF POSTMENOPAUSAL ESTROGEN
- Page 183 and 184: EFFECTS OF POSTMENOPAUSAL ESTROGEN
- Page 185 and 186: 10000 isoor i I ea '° a wan 20-24
- Page 187 and 188: ~SDt~rpa g~2~Q ~ !~fm~. b~e ~ ng jh
- Page 189 and 190: Is associated with an Increased ris
- Page 191 and 192: 188 Postmenopausal hormone therapy
- Page 193 and 194: group (P= 04001), and In this subgr
- Page 195 and 196: Treatmnent recommendations Based on
- Page 197 and 198: 21.Grodsteln F. Manson JE, Colditz
- Page 199 and 200: _ ORWIGNAL CONTIuBUTION 196 Postmen
- Page 201 and 202: showed no striking differences in H
- Page 203 and 204: (214 cases; P for trend=.72): howev
- Page 205 and 206: 202 HORMONE THERAPY USE AND RISK OF
- Page 207 and 208: mal studies, and laboratory studies
- Page 209 and 210: 206 HORMONE THERAPY USE AND RISK OF
- Page 211 and 212: 208 HORMONE THERAPY USE AND RISK OF
- Page 213 and 214: 210 ,lmcCII na: CLI I tr: tarty ver
- Page 215 and 216: 212 ,mucmai rimi &ronos farty bstro
- Page 217 and 218: 214 LntIucwu miau: rronos nary estr
- Page 219 and 220: XVI. PNharmacy Licensure Requiremen
- Page 221 and 222: XVI. Pharmacy Licensure Requirement
- Page 223 and 224: 220 Roster of Board of Pharmacy Ece
- Page 225 and 226: 050. 0l7404405400 Al-h. PeVbU 03283
- Page 227 and 228: Conclusions * Age is a powerful ris
- Page 229 and 230: Women's Health Initiative Trials of
- Page 231: Hormone Therapy after WHI * Change
- Page 235 and 236: 232 APhA Statement to the S
- Page 237 and 238: 234 APhA Statement to the S
- Page 239 and 240: 236 APhA Statement to the S
- Page 241 and 242: 238 APhA Statement to the S
- Page 243 and 244: 240 Written Testimony of Steven F.
- Page 245 and 246: 242 STATEMENT OF DAVID G. ADAMS On
- Page 247 and 248: 244 Report on State Laws and Regula
- Page 249 and 250: 246 Only one state, Utah, requires
- Page 251: 248 5. Compounding Copies of FDA-Ap
Statement<br />
of the<br />
American<br />
Pharmacists<br />
Associati<strong>on</strong><br />
230<br />
On <str<strong>on</strong>g>Bioidentical</str<strong>on</strong>g> <str<strong>on</strong>g>Horm<strong>on</strong>es</str<strong>on</strong>g>:<br />
Sound Science or Bad Medicine?<br />
Before the <str<strong>on</strong>g>Special</str<strong>on</strong>g> <str<strong>on</strong>g>Committee</str<strong>on</strong>g> <strong>on</strong> <strong>Aging</strong><br />
United States <str<strong>on</strong>g>Senate</str<strong>on</strong>g><br />
April 19, 2007<br />
American Pharmnacists.Associati<strong>on</strong><br />
1100 1 5 th St NW<br />
,4oJ . Suite 400<br />
Washingt<strong>on</strong>, DC 20005<br />
APhA (202) 628-4410 http:itwww.APhAneLorg
Change language